Ki-67 expression score correlates to survival rate in gastrointestinal stromal tumors (GIST);Escore de expressão de Ki-67 correlaciona-se com taxa de sobrevida em tumores estromais gastrointestinais (GIST)

Acta Cirurgica Brasileira

Volumn 27, Issue 5, 2012, Pages 315-321

  Neto, Ricardo Artigiani ^a   Logullo, Angela Flavia ^a   Stávale, João Norberto ^a   Lourenço, Laércio Gomes ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Gastrointestinal Stromal Tumors; Immunohistochemistry; Ki 67 Antigen; Survival Rate

Indexed keywords

CD34 ANTIGEN; DESMIN; GLUCURONOSYLTRANSFERASE 1A4; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P16; PROTEIN P53; PROTEIN S 100; STEM CELL FACTOR RECEPTOR; VIMENTIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CELL PROLIFERATION; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MITOSIS; MORPHOLOGY; MORTALITY; PROTEIN EXPRESSION; SCORING SYSTEM; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; BRAZIL; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; SURVIVAL RATE;

EID: 84862137500     PISSN: 01028650     EISSN: 16782674     Source Type: Journal    
DOI: 10.1590/S0102-86502012000500007     Document Type: Article

References (42)

1. Thomas RM, Sobin LH. Gastrointestinal cancer incidence and prognosis by a histologyc type population based data 1973-1987. Cancer. 1995;75(1 Suppl):154-70.
2. Appelman HD. Smooth muscle tumors of the gastrointestinal tract. What we know now that Stout didn't know. Am J Surg Pathol. 1986;10(Suppl 1):83-99.
3. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002;33(5):459-65.
4. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29(1):52-68.
5. Appelman HD. Smooth muscle tumors of the gastrointestinal tract. What we know now that Stout didn't know. Am J Surg Pathol. 1986;10(Suppl 1):83-99.
6. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152(5):1259-69.
7. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002;33(5):466-77.
8. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344(14):1052-6.
9. Reichardt P. Optimising therapy for GIST patients. EJC Supplements. 2006;4(Suppl 1):19-26.
10. Neves LRO, Oshima CTF, Artigiani-Neto R, Yanaguibashi G, Lourenco LG. Ki67 and p53 em tumores estromais gastrointestinais-GIST [Ki67 and p53 in gastrointestinal stromal tumors-GIST]. Arq Gastroenterol. 2009;46(2):116-20.
11. Buza N, Tavassoli FA. Comparative analysis of P16 and P53 expression in uterine malignant mixed mullerian tumors. Int J Gynecol Pathol. 2009;28(6):514-21.
12. Jeschke U, Schiessl B, Mylonas I, Kunze S, Kuhn C, Schulze S, Friese K, Mayr D. Expression of the proliferation marker Ki-67 and of p53 tumor protein in trophoblastic tissue of preeclamptic, HELLP, and intrauterine growth-restricted pregnancies. Int J Gynecol Pathol. 2006;25(4):354-60.
13. Lopes JM, Nesland JM, Reis-Filho JS, Holm R. Differential Ki67 and bcl-2 immunoexpression in solid-glandular and spindle cell components of biphasic synovial sarcoma: a double immunostaining assessment with cytokeratin and vimentin. Histopathology. 2002;40(5):464-71.
14. Choong PF, Akerman M, Willén H, Andersson C, Gustafson P, Baldetorp B, Fernö M, Alvegard T, Rydholm A. Prognostic value of Ki-67 expression in 182 soft tissue sarcomas. Proliferation--a marker of metastasis? APMIS. 1994;102(12):915-24.
15. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11(2):155-68.
16. Allred DC, Bryant J, Land S, Paik S, Fisher E, Julian T, Fisher B. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: Findings from NSABP Protocol B-24. Breast Cancer Res Treat. 2002;76(1):S36 (abstr #30).
17. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17(5):1474-81.
18. Reichardt P, Hogendoorn PC, Tamborini E, Loda M, Gronchi A, Poveda A, Schöffski P. Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. Semin Oncol. 2009;36(4):290-301.
19. Ando N, Goto H, Niwa Y, Hirooka Y, Ohmiya N, Nagasaka T, Hayakawa T. The diagnosis of GI stromal tumors with EUSguided fine needle aspiration with immunohistochemical analysis. Gastrointest Endosc. 2002;55(1):37-43.
20. Nakamura N, Yamamoto H, Yao T, Oda Y, Nishiyama K, Imamura M, Yamada T, Nawate H, Tsuneyoshi M. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol. 2005;36(7):828-37.
21. Pindzola JA, Palazzo JP, Kovatich AJ, Tuma B, Nobel M. Expression of p21WAF1/CIP1 in soft tissue sarcomas: a comparative immunohistochemical study with p53 and Ki-67. Pathol Res Pract. 1998;194(10):685-91.
22. Noguchi T, Sato T, Takeno S, Uchida Y, Kashima K, Yokoyama S, Müller W. Biological analysis of gastrointestinal stromal tumors. Oncol Rep. 2002;9(6):1277-82.
23. Abdulkader I, Cameselle-Teijeiro J, Gude F, Fraga M, Varela-Durán J, Barreto F, Forteza J. Predictors of malignant behaviour in gastrointestinal stromal tumours: a clinicopathological study of 34 cases. Eur J Surg. 2002;168(5):288-96.
24. Wong NA, Young R, Malcomson RD, Nayar AG, Jamieson LA, Save VE, Carey FA, Brewster DH, Han C, Al-Nafussi A. Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology. 2003;43(2):118-26.
25. Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology. 1990;17(6):489-503.
26. Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology. 2002;40(1):2-11.
27. Logullo AF, Lopes AB, Nonogaki S, Soares FA, Netto MM, Nishimoto IN, Brentani MM. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer. Oncol Rep. 2007;18(1):121-6.
28. Logullo AF, Kowalski LP, Nonogaki S, Miguel RE, Torloni H, Brentani RR. P53 overexpression in epidermoid carcinoma of the head and neck. Sao Paulo Med J. 1997;115(1):1349-55.
29. Jesus EC, Matos D, Artigiani R, Waitzberg AF, Goldenberg A, Saad SS. Assessment of staging, prognosis and mortality of colorectal cancer by tumor markers: receptor erbB-2 and cadherins. Acta Cir Bras. 2005;20(6):422-7.
30. Lustosa SA, Logullo A, Artigiani R, Saad SS, Goldenberg A, Matos D. Analysis of the correlation between p53 and bcl-2 expression with staging and prognosis of the colorectal adenocarcinoma. Acta Cir Bras. 2005;20(5):353-7.
31. Yamamoto H, Oda Y, Kawaguchi K, Nakamura N, Takahira T, Tamiya S, Saito T, Oshiro Y, Ohta M, Yao T, Tsuneyoshi M. c-kit and PDGFRA mutations in extragastrointestinal stromal tumor (gastrointestinal stromal tumor of the soft tissue). Am J Surg Pathol. 2004;28(4):479-88.
32. Kondo E, Yoshino T. Expression of apoptosis regulators in germinal centers and germinal center-derived B-cell lymphomas: Insight into B-cell lymphomagenesis. Pathol Int. 2007;57(7):391-7.
33. Siehl J, Thiel E. C-kit, GIST, and imatinib. Recent Results Cancer Res. 2007;176:145-51.
34. Kontogianni K, Demonakou M, Kavantzas N, Lazaris Ach, Lariou K, Vourlakou C, Davaris P. Prognostic predictors of gastrointestinal stromal tumors: a multi-institutional analysis of 102 patients with definition of a prognostic index. Eur J Surg Oncol. 2003;29(6):548-56.
35. Lane DP. p53 and human cancers. Br Med Bull. 1994;50(3):582-99.
36. Levine AJ. p53 the cellular gatekeeper for growth and division. Cell. 1997;88(3):323-31.
37. Martínez-Consuegra N, Baquera-Heredia J, de León-Bojorge B, Padilla-Rodríguez A, Hidalgo CO. Expression of p53 and BCI-2 as prognostic markers and for anatomical location in gastrointestinal stromal tumors (GIST). Clinico-pathological and immunohistochemistry study of 19 cases. Rev Gastroenterol Mex. 2006;71(3):269-78.
38. Sakurai S, Fukayama M, Kaizaki Y, Saito K, Kanazawa K, Kitamura M, Iwasaki Y, Hishima T, Hayashi Y, Koike M. Telomerase activity in gastrointestinal stromal tumors. Cancer. 1998;83(10):2060-6.
39. Michalany J. Técnica histológica em anatomia patológica: com instruções para o cirurgião, enfermeira e citotécnico. São Paulo: Epu; 1981.
40. Ricci R, Arena V, Castri F, Martini M, Maggiano N, Murazio M, Pacelli F, Potenza AE, Vecchio FM, Larocca LM. Role of p16/INK4a in gastrointestinal stromal tumor progression. Am J Clin Pathol. 2004;122(1):35-43.
41. Haller F, Gunawan B, von Heydebreck A, Schwagner S, Schulten HJ, Wolf-Salgó J, Langer C, Ramadori G, Sültmann H, Füzesi L. Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors. Clin Cancer Res. 2005;11(18):6589-97.
42. House MG, Guo M, Efron DT, Lilemoe KD, Cameron JL, Syphard JE, Hooker CM, Abraham SC, Montgomery EA, Herman JG, Brock MV. Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behavior. J Gastrointest Surg. 2003;7(8):1004-14.